June 12, 2025 01:42 PM EDT
Pharma
FDA+

In sur­prise, FDA ap­proves Uro­Gen's chemo-turned-gel drug af­ter neg­a­tive ad­comm vote

Max Gelman

Senior Editor

The FDA on Thurs­day ap­proved Uro­Gen’s ap­pli­ca­tion for its blad­der can­cer drug, de­spite a neg­a­tive vote from an ad­vi­so­ry com­mit­tee last …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

As­traZeneca inks AI drug R&D deal with Chi­nese phar­ma for $110M up­front 

Bris­tol My­ers gets a key strate­gist with 'Team Shib­s'; Idor­sia to change CEOs af­ter it 'hit a re­set but­ton'

Rein Ther­a­peu­tics study on clin­i­cal hold; Beam up­dates sick­le cell ther­a­py da­ta

With HIV pre­ven­tion un­der at­tack, how might Gilead’s new PrEP in­jec­tion fare?

No­vo Nordisk plans Phase 3 tri­als of oral, in­jectable amy­cretin for ear­ly 2026

sponsored

McKesson leads the charge in rev­o­lu­tion­iz­ing pre­ci­sion on­col­o­gy in com­mu­ni­ty prac­tices

A service from the Financial Times